During the last decades, the diagnosis and management of RA patients have been mainly dependent on autoantibody measurements, especially RF and ACPA, and the presence of autoantibodies is associated with more severe symptoms, joint damage, and increased mortality [4, 5]. Here, PRTN3 is linked to rheumatoid arthritis.